Journal Watch · Frontiers in Immunology · 2026
Novel nonsteroidal topical therapies for pediatric atopic dermatitis: a systematic review and network meta-analysis of randomized controlled trials.
Further head-to-head, long-term, and age-stratified trials are needed.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO/view/, identifier CRD420261400624.
TL;DR
Further head-to-head, long-term, and age-stratified trials are needed.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO/view/, identifier CRD420261400624.
Key findings
- No consistent increase in TEAEs or TRAEs was observed.
- Pairwise meta-analyses and sensitivity analysis were generally consistent with the primary findings.
- Subgroup analyses suggested timepoint- and age-related differences, but stratified evidence was limited.<h4>Conclusion</h4>Novel nonsteroidal topical therapies provide effective short-term steroid-sparing options for pediatric AD without a clear overall safety penalty.
- Further head-to-head, long-term, and age-stratified trials are needed.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO/view/, identifier CRD420261400624.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Pairwise vehicle-controlled meta-analyses, sensitivity analysis, and subgroup analyses by treatment duration and age were also performed.<h4>Results</h4>Twelve articles reporting 15 RCTs involving 3,994 pediatric patients were included. The network was largely centered on vehicle, with only one active-comparator trial. Most active regimens improved IGA-TS versus vehicle, except tapinarof 0.5% once daily. For EASI-75, five of ten evaluated active regimens showed significant benefit, while all six regimens evaluated for EASI-90 were superior to vehicle. Delgocitinib 0.5% twice daily ranked highest for IGA-TS and EASI-75, whereas difamilast 1% twice daily ranked highest for EASI-90.
Full abstract (original)
Background: <h4>Background</h4>Novel nonsteroidal topical therapies are increasingly used for pediatric atopic dermatitis (AD), but their comparative efficacy and safety remain unclear because direct active-comparator evidence is limited.<h4>Methods</h4>We conducted a systematic review and frequentist network meta-analysis (NMA) of randomized controlled trials (RCTs) evaluating novel nonsteroidal topical therapies in children with AD. The study was registered in PROSPERO (CRD420261400624). Efficacy outcomes included Investigator's Global Assessment treatment success (IGA-TS), Eczema Area and Severity Index 75 response (EASI-75), and EASI-90. Safety outcomes included treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs). Treatment nodes were defined by drug, concentration, and dosing frequency.
What they did: Pairwise vehicle-controlled meta-analyses, sensitivity analysis, and subgroup analyses by treatment duration and age were also performed.<h4>Results</h4>Twelve articles reporting 15 RCTs involving 3,994 pediatric patients were included. The network was largely centered on vehicle, with only one active-comparator trial. Most active regimens improved IGA-TS versus vehicle, except tapinarof 0.5% once daily. For EASI-75, five of ten evaluated active regimens showed significant benefit, while all six regimens evaluated for EASI-90 were superior to vehicle. Delgocitinib 0.5% twice daily ranked highest for IGA-TS and EASI-75, whereas difamilast 1% twice daily ranked highest for EASI-90.
Results & conclusions: No consistent increase in TEAEs or TRAEs was observed. Pairwise meta-analyses and sensitivity analysis were generally consistent with the primary findings. Subgroup analyses suggested timepoint- and age-related differences, but stratified evidence was limited.<h4>Conclusion</h4>Novel nonsteroidal topical therapies provide effective short-term steroid-sparing options for pediatric AD without a clear overall safety penalty. Further head-to-head, long-term, and age-stratified trials are needed.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO/view/, identifier CRD420261400624.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1906218 · PubMed 42559040.
Why it matters for pharma & biotech
- Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this Frontiers in Immunology study find?
Further head-to-head, long-term, and age-stratified trials are needed.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO/view/, identifier CRD420261400624.
What type of study is this?
It is a randomised / controlled clinical trial, published in Frontiers in Immunology in 2026. Pairwise vehicle-controlled meta-analyses, sensitivity analysis, and subgroup analyses by treatment duration and age were also performed.<h4>Results</h4>Twelve articles reporting 15 RCTs involving 3,994 pediatric patients were included.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1906218. PubMed ID: 42559040. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/novel-nonsteroidal-topical-therapies-for-pediatric-atopic-dermatitis-a-s-906218/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides